{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:28:05Z","timestamp":1791325685659,"version":"4.3.1"},"reference-count":40,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Left ventricular thrombus (LVT) remains a clinically significant complication following acute myocardial infarction (MI). Although its incidence has declined in the era of primary percutaneous coronary interventions (PCIs), the best treatment remains unclear. For decades, vitamin K antagonists (VKAs) such as warfarin have been the mainstay of therapy, supported by guidelines recommendations. However, the limitations of warfarin, including a narrow therapeutic range, the need for frequent monitoring, and food\/drug interactions, have spurred interest in direct oral anticoagulants (DOACs). This review summarizes the available evidence on anticoagulation strategies for LVT after MI, focusing on observational studies and recent randomized controlled trials. A total of 12 studies were included in this review: 9 retrospective cohorts and 3 randomized controlled trials. Patient populations ranged from small single-center cohorts to large multicenter registries. DOACs, compared with warfarin, were associated with a higher rate of thrombus resolution, a lower rate of stroke and systemic embolism, and a similar mortality. The usage of DOACs marginally reduced the rate of major bleeding compared with warfarin. The current evidence indicates that DOACs may offer comparable efficacy and potentially improved safety relative to warfarin, although most randomized trials remain small and underpowered for definitive conclusions. Larger, adequately powered studies are still required before DOACs can be routinely considered equivalent alternatives. The RIVAWAR randomized trial provides the strongest evidence to date regarding the use of DOACs in LVT after MI, but further large-scale randomized studies are required to establish definitive guidance. Until then, anticoagulation therapy including DOACs should be individualized, balancing the thromboembolic risk, bleeding risk, and practical considerations of anticoagulant use.<\/jats:p>","DOI":"10.3390\/jcm14227982","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:57:41Z","timestamp":1762851461000},"page":"7982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticoagulation Strategies for Left Ventricular Thrombus After Myocardial Infarction: A Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Adam","family":"Folman","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Toukan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer M.","family":"Kobo","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa 3200003, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4628-1840","authenticated-orcid":false,"given":"Ariel","family":"Roguin","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa 3200003, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maguli S.","family":"Barel","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, Hadera 3820302, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/heartjnl-2012-301962","article-title":"Left ventricular thrombus formation after acute myocardial infarction","volume":"98","author":"Delewi","year":"2012","journal-title":"Heart"},{"key":"ref_2","first-page":"236","article-title":"Left ventricular thrombi after STEMI in the contemporary era: Systematic review and meta-analysis of prevalence and predictors","volume":"68","author":"Robinson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ahj.2015.04.029","article-title":"Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: A prospective multicenter study","volume":"170","author":"Meurin","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.jacc.2019.01.031","article-title":"Left ventricular thrombus: Contemporary etiologies, treatment strategies, and outcomes","volume":"73","author":"McCarthy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","first-page":"1733","article-title":"Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after acute myocardial infarction","volume":"73","author":"Maniwa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"Kushner","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ehjcvp\/pvab057","article-title":"Apixaban vs. warfarin in patients with left ventricular thrombus: A prospective multicentre randomized clinical trial","volume":"8","author":"Alcalai","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cjco.2022.12.003","article-title":"Apixaban in Patients with Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial","volume":"5","author":"Youssef","year":"2022","journal-title":"CJC Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101978","DOI":"10.1016\/j.jacadv.2025.101978","article-title":"Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT","volume":"4","author":"Shah","year":"2025","journal-title":"JACC Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/ehjcvp\/pvaa096","article-title":"The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction","volume":"7","author":"Jones","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_16","first-page":"1","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"2","author":"Wells","year":"2014","journal-title":"Ott. Hosp. Res. Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2459\/JCM.0000000000001683","article-title":"Efficacy of direct oral anticoagulants vs. warfarin in left ventricular thrombus in myocardial infarction: Systematic review and meta-analysis","volume":"26","author":"Attachaipanich","year":"2025","journal-title":"J. Cardiovasc. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s43044-021-00164-7","article-title":"Rivaroxaban versus warfarin for the management of left ventricle thrombus","volume":"73","author":"Albabtain","year":"2021","journal-title":"Egypt. Heart J."},{"key":"ref_20","first-page":"S143","article-title":"Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction","volume":"34","author":"Jaidka","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1570161120666221003104821","article-title":"Efficacy and Safety of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus After Acute Anterior Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Intervention","volume":"20","author":"Liang","year":"2022","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12959-024-00632-5","article-title":"Evaluation of the efficacy and safety of rivaroxaban compared to warfarin in patients with left ventricular apical thrombus: A randomized clinical trial","volume":"22","author":"Mansouri","year":"2024","journal-title":"Thromb. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.amjmed.2024.10.042","article-title":"Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists for Left Ventricular Thrombus: A Global Retrospective Study","volume":"138","author":"Yao","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00380-021-01921-z","article-title":"Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction","volume":"37","author":"Zhang","year":"2022","journal-title":"Heart Vessels."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.jtha.2023.06.036","article-title":"Warfarin faring better: Vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials","volume":"21","author":"Eikelboom","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sgarra, L., Desantis, V., Matteucci, A., Caccavo, V.P., Troisi, F., Di Monaco, A., Mangini, F., Katsouras, G., Guaricci, A.I., and Dadamo, M.L. (2025). Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030660"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI (PIONEER AF-PCI)","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation (RE-DUAL PCI)","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after ACS or PCI in atrial fibrillation (AUGUSTUS)","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"88","article-title":"RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves\u2014The search continues","volume":"2014","author":"Shazly","year":"2014","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3000605251326764","DOI":"10.1177\/03000605251326764","article-title":"Embolic stroke complicating left ventricular thrombus in Takotsubo syndrome: A case report","volume":"53","author":"Lei","year":"2025","journal-title":"J. Int. Med. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/eurheartj\/ehad431","article-title":"Artificial intelligence in detecting left atrial appendage thrombus by transthoracic echocardiography and clinical features: The Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry","volume":"45","author":"Pieszko","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic Therapy in Patients with Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients with Coronary Artery Disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ahj.2009.03.020","article-title":"Incidence of early left ventricular thrombus after acute anterior wall myocardial infarction in the primary coronary intervention era","volume":"157","author":"Osherov","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Choi, J.H., Kim, W., Kim, Y.T., Cho, J., Shin, S.Y., Kim, C., and Kim, J.B. (2022). Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients with Intermediate Stroke Risk. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.849474"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/bcp.13985","article-title":"A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants","volume":"85","author":"Afzal","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2147\/PPA.S204246","article-title":"Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: A cross-sectional study","volume":"13","author":"Ng","year":"2019","journal-title":"Patient Prefer. Adherence"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.23736\/S2724-5683.24.06546-3","article-title":"Italian Registry in the Setting of Atrial Fibrillation Ablation with Rivaroxaban\u2014IRIS","volume":"72","author":"Lavalle","year":"2024","journal-title":"Minerva Cardiol. Angiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:26:29Z","timestamp":1762853189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/7982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":40,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14227982"],"URL":"https:\/\/doi.org\/10.3390\/jcm14227982","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}